Epclusa Access | Velpatasvir And Sofosbuvir Tablet Breastfeeding

It is recommended to breastfeed exclusively for six months and then while introducing to other food sources extend it to twelve months. In this duration most mothers will need help of some sort of medication, It could be for short term like could and flue or it could be something chronic like Arthritis or Diabetes and here comes the question of safety of medication in use. In this post we will figure out what is Epclusa Access | Velpatasvir And Sofosbuvir Tablet and whether its safe to use Epclusa Access | Velpatasvir And Sofosbuvir Tablet while nursing or not.

What is Epclusa Access | Velpatasvir And Sofosbuvir Tablet used for?


EPCLUSA™ is indicated for the treatment of adult patients with chronic hepatitis C virus (HCV) genotype 1, 2, 3, 4, 5, or 6 infection [see Dosage and Administration (2.2) and Clinical Studies (14)]: without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin. EPCLUSA is a fixed-dose combination of sofosbuvir, a hepatitis C virus (HCV) nucleotide analog NS5B polymerase inhibitor, and velpatasvir, an HCV NS5A inhibitor, and is indicated for the treatment of adult patients with chronic HCV genotype 1, 2, 3, 4, 5, or 6 infection (1): without cirrhosis or with compensated cirrhosis with decompensated cirrhosis for use in combination with ribavirin

Is using Epclusa Access | Velpatasvir And Sofosbuvir Tablet unsafe in breastfeeding? Can there be bad consequences for baby if I use it while breastfeeding?

Epclusa Access | Velpatasvir And Sofosbuvir Tablet low risk for breastfeeding
Velpatasvir and Sofosbuvir are the two main ingredients of Epclusa Access | Velpatasvir And Sofosbuvir Tablet. Based on our individual analysis of Velpatasvir and Sofosbuvir we can safely say that Epclusa Access | Velpatasvir And Sofosbuvir Tablet has low risk while breastfeeding. Below we have summarized the usage of Velpatasvir and Sofosbuvir while breastfeeding, we recommend you to go through it for better understanding of your usage.

Epclusa Access | Velpatasvir And Sofosbuvir Tablet Breastfeeding Analsys


Velpatasvir while Breastfeeding

Low Risk

CAS Number: 1377049-84-7

Usually used in combination with sofosbuvir in the treatment of hepatitis C. Since the last update we have not found published data on its excretion in breast milk. Its pharmacokinetic data (high molecular weight and very high percentage of protein binding) make it very unlikely that significant amounts would pass into breast milk, therefore it would not be necessary to stop breastfeeding when taking this medication on its own or in combination with sofosbuvir (Lactmed 2016). See below the information of these related products:

Sofosbuvir while Breastfeeding

Low Risk

CAS Number: 1190307-88-0

Usually used in combination with Ledispavir in the treatment of hepatitis C. Since the last update we have not found published data on its excretion in breast milk. Its pharmacokinetic data (moderately elevated molecular weight, good percentage of protein binding and very short half-life) impedes its passage to breast milk in significant amounts, so although there is disagreement (Thompson 2016), some authors consider that treatment with sofosbuvir, alone or in combination with ledipasvir is not contraindicated during breastfeeding (Spera 2016). See below the information of these related products:


Epclusa Access | Velpatasvir And Sofosbuvir Tablet Breastfeeding Analsys - 2


Velpatasvir while Breastfeeding

CAS Number: 1377049-84-7

Is Epclusa Access | Velpatasvir And Sofosbuvir Tablet safe while breastfeeding

Velpatasvir has not been studied in nursing mothers being treated for hepatitis C infection. Because it is greater than 99.5% bound to maternal plasma proteins, amounts in breastmilk are likely to be very low. If velpatasvir used alone or in combination with sofosbuvir is required by the mother, it is not a reason to discontinue breastfeeding. Some sources recommend against breastfeeding when velpatasvir is used with ribavirin. Hepatitis C is not transmitted through breastmilk[1][2] and breastmilk has been shown to inactivate hepatitis C virus (HCV).[3][4] However, the Centers for Disease Control recommends that mothers with HCV infection should consider abstaining from breastfeeding if their nipples are cracked or bleeding. It is not clear if this warning would apply to mothers who are being treated for hepatitis C. Infants born to mothers with HCV infection should be tested for HCV infection; because maternal antibody is present for the first 18 months of life and before the infant mounts an immunologic response, nucleic acid testing is recommended.[1][2]

Sofosbuvir while Breastfeeding

CAS Number: 1190307-88-0 1620486

Sofosbuvir has not been studied in nursing mothers being treated for hepatitis C infection. If sofosbuvir alone or in combination with ledipasvir (Harvoni) is required by the mother, it is not a reason to discontinue breastfeeding.[1] Some sources recommend against breastfeeding when sofosbuvir is used with ribavirin. Hepatitis C is not transmitted through breastmilk[2][3] and breastmilk has been shown to inactivate hepatitis C virus (HCV).[4][5] However, the Centers for Disease Control recommends that mothers with HCV infection should consider abstaining from breastfeeding if their nipples are cracked or bleeding. It is not clear if this warning would apply to mothers who are being treated for hepatitis C. Infants born to mothers with HCV infection should be tested for HCV infection; because maternal antibody is present for the first 18 months of life and before the infant mounts an immunologic response, nucleic acid testing is recommended.[2][3]


Epclusa Access | Velpatasvir And Sofosbuvir Tablet safe for breastfeeding

What if I already have used Epclusa Access | Velpatasvir And Sofosbuvir Tablet?

During whole lactation period you shall first discuss with your doctor and then together you shall decide whether you shall take that drug or not however if you have already taken Epclusa Access | Velpatasvir And Sofosbuvir Tablet then you shall inform your doctor, But you should not be worried too much as Epclusa Access | Velpatasvir And Sofosbuvir Tablet comes in category of low risk drug.


My health care provider has asked me to use Epclusa Access | Velpatasvir And Sofosbuvir Tablet, what to do?

Epclusa Access | Velpatasvir And Sofosbuvir Tablet comes in category of low risk and if your doctor is aware that you are breastfeeding it should be ok to use without much concerns.


If I am using Epclusa Access | Velpatasvir And Sofosbuvir Tablet, will my baby need extra monitoring?

Not much


Who can I talk to if I have questions about usage of Epclusa Access | Velpatasvir And Sofosbuvir Tablet in breastfeeding?

US
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday

UK
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700

Australia
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week

Canada
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week

Drug Brands with same Active ingredients